We don’t have the full picture when it comes to
Post# of 157788
(Total Views: 599)
Posted On: 06/10/2022 5:38:57 PM
We don’t have the full picture when it comes to NASH so wait and see. We’ve always had to do a phase 3. Didn’t matter how good the results were. We still need a partner to conduct the trial.
Let’s say we start a phase 3 with a big partner we won’t see much more than 1-3 Billon market cap. Better than where we are at. I’d assume we will stay around 1-3 dollars.
Personally until the BLA is done I don’t think we see double digits. Even with partners and phase 3 trials being conducted. Maybe short lived but until we have revenue and an approval we will not see any substantial market cap for awhile imo. Meaning 10 Billon plus.
Sorry if this post is all over the place, exhausted, but I think people understand what I’m trying to say.
Regardless I do not believe these prices will last. We will find a new bottom to talk about hopefully being around 3 dollars.
Let’s say we start a phase 3 with a big partner we won’t see much more than 1-3 Billon market cap. Better than where we are at. I’d assume we will stay around 1-3 dollars.
Personally until the BLA is done I don’t think we see double digits. Even with partners and phase 3 trials being conducted. Maybe short lived but until we have revenue and an approval we will not see any substantial market cap for awhile imo. Meaning 10 Billon plus.
Sorry if this post is all over the place, exhausted, but I think people understand what I’m trying to say.
Regardless I do not believe these prices will last. We will find a new bottom to talk about hopefully being around 3 dollars.
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36